Current Use for Old Antibacterial Agents: Polymyxins, Rifamycins, and Aminoglycosides

被引:51
作者
Chen, Luke F. [1 ]
Kaye, Donald [2 ,3 ]
机构
[1] Duke Univ, Med Ctr, Dept Med, Div Infect Dis & Int Hlth, Durham, NC 27710 USA
[2] Drexel Univ, Coll Med, Philadelphia, PA 19035 USA
[3] Dept Med, Gladwyne, PA 19035 USA
关键词
Rifaximin; Pharmacokinetics; Pharmacodynamics; Toxicity; Polymyxins; Aminoglycoside; Rifampin; VENTILATOR-ASSOCIATED PNEUMONIA; RESISTANT PSEUDOMONAS-AERUGINOSA; ONCE-DAILY TOBRAMYCIN; CYSTIC-FIBROSIS; STAPHYLOCOCCUS-AUREUS; IN-VITRO; CLOSTRIDIUM-DIFFICILE; ACINETOBACTER-BAUMANNII; SYNERGISTIC ACTIVITY; COLISTIN METHANESULFONATE;
D O I
10.1016/j.idc.2009.06.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This article reviews three classes of antibacterial agents that are uncommonly used in bacterial infections and therefore can be thought of as special-use agents. The polymyxins are reserved for gram-negative bacilli that are resistant to virtually all other classes of drugs. Rifampin is used therapeutically, occasionally as a companion drug in treatment of refractory gram-positive coccal infections, especially those involving foreign bodies. Rifaximin is a new rifamycin that is a strict enteric antibiotic approved for treatment of traveler's diarrhea and is showing promise as a possible agent for refractory Clostridium difficile infections. The aminoglycosides are used mainly as companion drugs for the treatment of resistant gram-negative bacillary infections and for gram-positive coccal endocarditis.
引用
收藏
页码:1053 / +
页数:24
相关论文
共 144 条
[1]   Rifaximin: A novel nonabsorbed rifamycin for gastrointestinal disorders [J].
Adachi, JA ;
DuPont, HL .
CLINICAL INFECTIOUS DISEASES, 2006, 42 (04) :541-547
[2]   Therapeutic drug monitoring of gentamicin: Evaluation of five nomograms for initial dosing at Al-Amiri Hospital in Kuwait [J].
Al-Lanqawi, Yousef ;
Capps, Phillip ;
Abdel-hamid, Mohamed ;
Abulmalek, Kefaya ;
Phillips, Dotun ;
Matar, Kamal ;
Sharma, Prem ;
Thusu, Anil .
MEDICAL PRINCIPLES AND PRACTICE, 2007, 16 (05) :348-354
[3]   Aminoglycoside-induced vestibular injury: Maintaining a sense of balance [J].
Ariano, Robert E. ;
Zelenitsky, Sheryl A. ;
Kassum, Diamond A. .
ANNALS OF PHARMACOTHERAPY, 2008, 42 (09) :1282-1289
[4]   Aminoglycoside-associated nephrotoxicity in the elderly [J].
Baciewicz, AM ;
Sokos, DR ;
Cowan, RI .
ANNALS OF PHARMACOTHERAPY, 2003, 37 (02) :182-186
[5]   Update on rifampin and rifabutin drug interactions [J].
Baciewicz, Anne M. ;
Chrisman, Cary R. ;
Finch, Christopher K. ;
Self, Timothy H. .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2008, 335 (02) :126-136
[6]  
Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564
[7]   A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides [J].
Bailey, TC ;
Little, JR ;
Littenberg, B ;
Reichley, RM ;
Dunagan, WC .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (05) :786-795
[8]   The treatment of respiratory pseudomonas infection in cystic fibrosis - What drug and which way? [J].
Banerjee, D ;
Stableforth, D .
DRUGS, 2000, 60 (05) :1053-1064
[9]   Once daily aminoglycoside therapy - Is it less toxic than multiple daily doses and how should it be monitored? [J].
Barclay, ML ;
Kirkpatrick, CMJ ;
Begg, EJ .
CLINICAL PHARMACOKINETICS, 1999, 36 (02) :89-98
[10]   EXPERIENCE OF ONCE-DAILY AMINOGLYCOSIDE DOSING USING A TARGET AREA UNDER THE CONCENTRATION-TIME CURVE [J].
BARCLAY, ML ;
DUFFULL, SB ;
BEGG, EJ ;
BUTTIMORE, RC .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1995, 25 (03) :230-235